Skip to main content
. 2012 Jul;50(7):2289–2298. doi: 10.1128/JCM.00840-12

Table 4.

HPV IU/GE detection per 5 μl in both single and multiple infectionsa

HPV type No. of HPV IU/GE No. of data sets detecting HPV by the following assay/total no. of data sets using the assay (%):
Commercial assays
In-house assaysa
Linear array (Roche) InnoLiPA (Innogenetics) CLART HPV 2/3 (Genomica) Digene HPV genotyping LQ Papillocheck microarray (Greiner Bio-One) PCR Luminex (Multimetrix) Digene HPV genotyping RH (Qiagen) Hybribio microarray DEIA line probe (Lab.Bio) EASYChip (King Car) LCD array (Chiron) Other commercialb All assays Line blot PCR-RFLP Luminex PGMY-CHUV Type-specific PCR Real-time PCR PCR sequencing Dot blot Other in-housec
16 5 3/17 10/12 8/8 2/3 4/4 3/3 2/2 2/2 2/2 2/2 7/9 85/127 (67) 3/10 2/7 7/7 4/6 4/6 4/5 3/5 1/2 3/3
16 50 16/17 12/12 3/3 7/9 118/127 (93) 9/10 5/7 5/6 5/5 4/6 2/2
16 500 17/17 1/2 9/9 125/127 (98) 10/10 7/7 6/6 5/6 5/6
18 5 3/17 9/12 5/8 3/3 NTc 3/3 2/2 2/2 2/2 2/2 6/9 72/119 (60) 2/10 1/7 5/7 4/6 3/6 3/5 3/5 2/2 2/3
18 50 17/17 12/12 5/8 6/9 106/119 (89) 7/10 3/7 7/7 5/6 4/6 4/5 4/6
18 500 8/8 1/2 9/9 108/119 (91) 8/10 6/6 5/6 5/5
6 50 4/17 11/12 6/8 4/4 2/3 1/2 2/2 2/2 2/2 8/8 64/110 (58) 2/10 3/7 2/6 5/6 4/5 2/4 2/6 1/3
6 500 17/17 12/12 8/8 NT 3/3 NT 2/2 97/110 (88) 8/10 6/7 4/6 6/6 4/5 3/4 3/6 1/2 3/3
11 50 4/17 12/12 8/8 4/4 3/3 2/2 2/2 2/2 2/2 6/8 79/109 (72) 6/10 4/7 6/6 5/6 4/5 2/4 1/6 2/2 3/3
11 500 16/17 NT NT 8/8 100/109 (92) 8/10 7/7 6/6 4/5 3/4 2/6
31 50 4/17 12/12 8/8 1/3 1/4 2/2 2/2 2/2 4/9 52/118 (44) 3/10 3/7 3/6 2/6 4/5 2/3
31 500 15/17 3/3 4/4 1/2 84/118 (71) 5/10 3/7 5/7 5/6 4/6 1/6 1/2 3/3
33 50 4/17 10/12 8/8 3/3 4/4 3/3 2/2 2/2 2/2 2/2 2/2 7/8 76/117 (65) 4/10 2/7 4/7 5/6 3/6 5/5 2/2 3/3
33 500 16/17 8/8 97/117 (83) 7/10 3/7 5/7 4/6 2/6
35 50 4/17 12/12 8/8 3/3 3/3 2/2 2/2 2/2 2/2 6/9 70/118 (59) 5/10 1/7 5/7 5/6 3/6 2/5 1/6 1/2 3/3
35 500 14/17 4/4 9/9 98/118 (83) 8/10 2/7 7/7 4/6 4/5 3/6 2/2
39 50 4/17 9/12 4/4 3/3 1/2 2/2 2/2 2/2 5/9 45/118 (38) 3/10 3/7 3/6 1/6 4/5 1/2 2/3
39 500 15/17 11/12 1/8 7/9 77/118 (65) 6/10 5/7 6/6 3/6 5/5 3/3
45 50 4/17 7/12 1/8 3/3 3/4 3/3 2/2 2/2 2/2 2/2 9/9 71/118 (60) 7/10 2/7 6/7 5/6 3/6 5/5 2/6 2/2 2/3
45 500 17/17 12/12 4/8 4/4 1/2 98/118 (83) 9/10 2/7 7/7 3/6
51 50 4/17 11/12 8/8 1/3 4/4 3/3 1/2 2/2 2/2 2/2 8/9 69/117 (59) 3/9 1/7 5/7 5/6 3/6 4/5 2/3
51 500 15/17 12/12 3/3 2/2 92/117 (79) 5/9 2/7 6/7 6/6 4/6 5/5 1/2 3/3
52 50 4/17 11/12 8/8 4/4 3/3 2/2 2/2 2/2 2/2 9/9 79/117 (67) 4/9 3/7 7/7 5/6 3/6 5/5 1/6 1/2 3/3
52 500 17/17 12/12 1/3 2/2 98/117 (84) 7/9 3/7
56 50 4/17 10/12 3/3 4/4 3/3 2/2 2/2 2/2 7/9 63/118 (53) 5/10 1/7 6/7 3/6 3/6 4/5 2/2 3/3
56 500 15/17 12/12 3/8 86/118 (73) 8/10 7/7 4/6
58 50 4/17 1/12 8/8 1/3 3/4 1/3 2/2 2/2 2/2 2/2 7/9 62/118 (52) 4/10 4/7 6/7 5/6 3/6 3/5 1/2 2/3
58 500 17/17 5/12 3/3 2/3 1/2 9/9 91/118 (77) 7/10 5/7 7/7 4/5 3/3
59 50 3/17 1/12 7/8 1/3 4/4 3/3 1/2 2/2 2/2 2/2 7/9 52/117 (44) 3/9 1/7 5/7 4/6 2/6 1/5 1/2 1/3
59 500 16/17 2/12 2/3 2/2 2/2 8/9 80/117 (68) 6/9 2/7 6/7 5/6 3/6 3/5 2/3
66 50 4/17 11/12 8/8 3/3 3/4 3/3 2/2 2/2 2/2 2/2 6/7 75/113 (66) 4/9 3/7 6/7 5/6 3/5 3/6 1/2 3/3
66 500 14/17 4/4 2/2 7/7 95/113 (84) 7/9 6/7 7/7 3/5 4/6
68a 50 1/12 2/2 2/6 10/61 (16) 1/5 3/6 1/1
68a 500 nt 4/12 NT NT NT NT NT 17/61 (28) 2/8 4/6 NT NT NT 1/1
68b 50 4/17 11/12 4/4 3/3 1/2 2/2 2/2 2/2 2/2 7/9 53/114 (46) 3/10 1/7 3/7 5/6 2/5 1/3 1/3
68b 500 14/17 11/12 73/114 (64) 5/10 2/7 6/7 1/2 3/3
a

Includes laboratories with multiple false positives. Detection with an input volume of 50 μl is classified with data for the next 10-fold dilution compared to input with 5 μl. Input with 10 or 15 μl is classified with data for the same dilution compared to input with 5 μl. Other in-house assays include the following, used by one laboratory each: in-house PCR enzyme immunoassay, in-house multiplex PCR gel analysis, and in-house mass spectrometry. RFLP, restriction fragment length polymorphism.

b

Other commercial assays included the following, used by one laboratory each: Medical Device Microarray, PnE HPV genotyping Luminex, Ampliquality reverse hybridization, Panagene microarray, PANArray HPV, GenoFlow HPV array kit, MolGENTIX multiplex fluorescent PCR, Hybrid Capture 2, Sacace high-risk screen, and Genoserch HPV-31 Luminex.

c

NT, not tested.